SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):  September 14, 2007

 

ADVANCED CELL TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-50295

 

87-0656515

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification Number)

 

1201 Harbor Bay Parkway, Alameda, California 94502

(Address of principal executive offices, including zip code)

 

(510) 748-4900

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c))

 

 



 

ITEM 1.01                              Entry into a Material Definitive Agreement.

Effective September 15, 2007, the Company and Robert Peabody entered into a consulting agreement.  Mr. Peabody will provide consulting services to the Company.  The term of the consulting agreement is for three (3) months and provides for a monthly consulting fee of approximately $17,000.

ITEM 5.02                              Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officer.

Effective as of September 14, 2007, the Company’s current Vice President, Grant Administration, Robert Peabody, stepped down in that capacity and terminated his employment arrangement with the Company.  Mr. Peabody will continue to be available as a consultant to assist with transition issues. The material terms of Mr. Peabody’s consulting agreement are discussed in Item 1.01 above.

2



 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADVANCED CELL TECHNOLOGY, INC.

 

 

 

 

 

 

 

By:

/s/ William M. Caldwell, IV

 

 

William M. Caldwell, IV

 

 

Chief Executive Officer

 

 

 

Dated: September 20, 2006

 

 

 

3